MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

A large new study has confirmed the clinical relevance of a pharmacogenomic score that could help tailor leukaemia treatment ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Scientists at Indiana University School of Medicine have identified a new approach that could transform treatment for acute ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of ...

Bleeding gums is a common manifestation in leukaemia, more so in acute leukaemias like Acute Myeloid leukaemia (AML) and ...

Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.